In short. Real exosome evidence would have to begin with identity and manufacture: a product shown by a specified method to contain what its name claims, made to stated release criteria. It would then need a dose stated as a number and controlled trials that separate the injected material from any needling or laser performed with it.
Key points
- A product must be shown to contain what its name claims, by a specified method.
- Manufacture needs a defined source, a reproducible process and stated release criteria.
- A dose is a number that means the same thing in two laboratories.
- Controlled trials must separate the injected material from any needling or laser.
- Approval is the start of surveillance, not the end of the obligation.
What would change the verdict
This review has set out what the evidence does not support. It is worth stating, just as plainly, what would change the verdict. None of the requirements below is unusual or unreasonable. Each is the ordinary path a regulated biological product follows, and the fact that the path has been skipped is a commercial decision rather than a scientific impossibility.
Identity
A product would have to be shown to contain what its name claims, by a specified method, using a specified set of markers, with the result reported as a number. The measurement would have to be reproducible by a laboratory with no interest in the outcome, and it would have to be repeated on batches drawn from routine production rather than on a sample prepared for the occasion. A name printed on a label is not an identity test, and a certificate that repeats the name establishes nothing.
Manufacture
The cell or tissue source would need to be defined and screened, the process written down and reproducible, and the release criteria for each batch stated in advance. A validated step that reduces the risk of infection would be needed, together with evidence that the step leaves the material in a state matching what was tested. Where those two requirements conflict, the conflict has to be resolved and documented rather than avoided. Release criteria are what make a product the same thing from one batch to the next.
Why a dose must be a number
No result can be repeated or compared without a stated amount of a characterised material. Until a product can state what is injected in a unit that means the same thing in two laboratories, every published finding describes a different intervention from the one being offered.
Trials
The evidence would have to come from controlled studies in people: a defined population, an outcome decided in advance, assessment by someone who does not know which treatment was given, and follow-up long enough to catch effects that appear late.
| Requirement | What it would have to show | Why it matters | What the page says is missing |
|---|---|---|---|
| Identity | That the product contains what its name claims, by a specified method and markers, reported as a number | A label is not an identity test | A reproducible identity assay |
| Manufacture | A defined and screened source, a written reproducible process and stated release criteria | Release criteria make one batch the same as the next | Release criteria and a validated process |
| Dose | An amount of characterised material in a unit two laboratories can reproduce | Results cannot be repeated or compared without it | A stated amount |
| Controlled trials | A defined population, a pre-decided outcome, blinded assessment and adequate follow-up | An uncontrolled result cannot be attributed | Separation of the material from the procedure |
| Post-approval surveillance | Collection of adverse events, linkage to batches and withdrawal of stock | It makes a rare complication visible | A system that can withdraw stock |
What would a controlled trial have to separate?
Where the injected material is combined with a procedure that injures the skin, the design would have to separate them, because a result that cannot be attributed to one or the other answers nothing about either.
Surveillance after approval
A product that reached the market would still need a system that collects adverse events, links them to batches, and can withdraw stock. Approval is the start of that obligation rather than the end of it, and the systems that do this work are what make a rare complication visible at all.
Which requirements are ordinary rather than unusual?
The list is the ordinary path of a regulated biological product, not a set of demands invented for this category. An identity assay, a defined dose of a characterised material and controlled trials are what any product of this kind is expected to supply. If that work were done, the verdict on these products could change, in either direction. That is what makes the current position a gap rather than a conclusion: the question has not been answered, it has been bypassed.
Sources
- American Society of Plastic Surgeons: guidance on the evidence base for injectable treatments
- National Institute for Health and Care Excellence: guidance on unlicensed injectable products
- Cochrane Library: systematic reviews on skin rejuvenation interventions
Source links open each organisation's search results for the topic. Document-level confirmation is pending the reviewer's sign-off.
Internal links
Frequently asked questions
What identity testing would an exosome product need?
A specified method, a specified set of markers, and a result reported as a number, measured by a laboratory with no interest in the outcome and repeated on batches drawn from routine production rather than on a sample prepared for the occasion. The point is that the measurement has to be one somebody else could repeat and get the same answer.
Why does a dose have to be a number?
Because no result can be repeated or compared without a stated amount of a characterised material. Until a product can state what is injected in a unit that means the same thing in two laboratories, every published finding describes a different intervention from the one being offered, and nothing can be added up.
How would a trial separate the injected material from a needling procedure?
By design: groups that receive the same procedure with the material and with a control, assessed by someone who does not know which was given, with the outcome decided in advance. Where the two are always given together, a result attributable to one cannot be attributed to the other, and the study answers nothing about either.
Risks & Limitations
- No product marketed as an exosome injectable has been through the approval process that would establish what it contains or what it does.
- Birth tissue derived material carries an infection risk when it is injected, and serious infections have been reported after such injections.
- The evidence behind most claims comes from laboratory work, animal models or uncontrolled case series, none of which establishes an effect in people.
- Regulatory status differs by country, and in most markets there is no approval for these products in any injectable use.
- Nothing on this site is a recommendation for or against any treatment, and it does not assess individual cases.
When to Seek Care
- Spreading redness, heat, swelling or discharge at an injection site: have it assessed promptly.
- Fever, or feeling unwell with a painful injected area: seek medical care without waiting.
- Severe or worsening pain, blistering, or skin breakdown where something was injected.
- Any new and persistent symptom after a treatment: have it assessed by a clinician who can examine you.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.